Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCT-305
- Development stage
- Preclinical
- Lead developer
- ITL Pharma
- Modality
- Small Molecules
01
Overview
BCT-305 is an investigational pharmaceutical candidate reported as a small-molecule thyroid hormone receptor agonist program for hypothyroidism. Publicly available pipeline references are sparse, but the asset has been described as a dual thyroid hormone receptor alpha and thyroid hormone receptor beta agonist being developed by Itl Pharma, with preclinical development activity reported for hypothyroidism. Because source detail is limited and largely confined to pipeline aggregation databases rather than primary company disclosures, the exact molecular identity, formulation, route, and clinical development history remain insufficiently characterized in the public domain.
- Other names
- BCT-305/BCT-306
Beyond the preview
Go deeper on BCT-305.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCT-305.